A Senate bill that would give generic companies a pathway for suing brand-name rivals when denied access to needed samples would lower federal government spending by $3.3 billion on medicines, according to a new analysis.
Known as the CREATES Act, the legislation would also yield about $600 million in revenue through lower premiums in federal health plans, generating a combined impact of $3.9 billion on the federal budget from 2019 through 2028, according to the report from the Congressional Budget Office. The bill is expected to accelerate entry of affected lower-cost generic or biosimilar medicines by one to two years.
About the Author Reprints
If failing memory serves, the very first REMS was to allow Celgene to put thalidomide (that accursed drug product) into the American pharma market safely. Now … it is viewed rather differently. That flexible regulatory solution is now being used to castigate Celgene, as mentioned above.
I wonder if that nugget will come up in the already toxic NJ US senate race?